Tamsulosin Hydrochloride Capsule
Product Images NDC 68071-2561

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-2561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2561 9)

This is a description of medication packaging from NuCare Pharmaceuticals, Inc. The medication is Tamsulosin Hydrochloride in capsule form with a dosage of 0.4mg. The package contains 90 capsules and each capsule contains Tamsulosin Hydrochloride. The capsules are olive green opaque and orange opaque with an imprint of 'D' on the cap and 53 on the body. The lot number for the capsules is 00000 and the expiration date is 00-00. The medication should be stored at a controlled temperature of 68-77°F and kept out of reach of children. If you experience any side effects with this medication, you should contact your doctor or call 1-800-FDA-1088.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

The text appears to be a figure caption for a graph depicting the mean plasma concentrations of Tamsulosin Hydrochloride capsules administered at 0.4 mg under fasted and fed conditions. The figure also includes a time axis.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A graph is shown in Figure 2A depicting the mean change from baseline in Total AUA Symptom Score ranging from 0 to 35 from Study 1. The treatment groups involved were -OO-0-08mg_~A= A -A04my_ and O30 Placebo. The duration of treatment ranged from 1 to 13 weeks with varying sample sizes.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Figure 2B shows the mean change in Total American Urological Association (AUA) Symptom Score from baseline on different treatment protocols. The treatments compared include 0.08mg and 0.4mg LNt, and Placebo. The study lasted for up to 13 weeks. The figure provides information of the number of participants in each group and the time frame of the study.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

This is a graph (Figure 3A) that shows the mean increase in peak urine flow rate (in L/sec) in Study 1. The treatments 0.08mg and 0.4mg are compared to a placebo, with the mean change in urine flow rate (in mL/sec) shown on the vertical axis. The duration of treatment (in weeks) is shown on the horizontal axis. There are different sample sizes for each treatment group.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.